DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactIPO

Symbiotec Pharmalab IPO: Price band, lot size, GMP, listing date and other key details

IndiaIPO 1d ago·21 Aug 2026, 3:00 pm

IPO IndiaIPO

Symbiotec Pharmalab is preparing to launch its initial public offering (IPO) to raise capital for its business operations. The company is a prominent player in the pharmaceutical sector, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs). The IPO is expected to open for subscription soon, allowing retail investors to participate in the company's growth story.

For investors, this IPO presents an opportunity to invest in a company with a strong foothold in the pharmaceutical industry. The company has a diverse product portfolio and a growing customer base. The IPO will help the company fund its expansion plans, which could lead to increased profitability and market share in the future.

Investors should keep an eye on the company's financial performance, the demand for its products, and the overall market sentiment during the subscription period. The IPO's success will depend on the pricing and the company's ability to meet its growth targets.